Ferraironi A - Search Results

1

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.

Lopez M, Vici P, Di Lauro K, Conti F, Paoletti G, Ferraironi A, Sciuto R, Giannarelli D, Maini CL. Lopez M, et al. Among authors: ferraironi a. J Clin Oncol. 1998 Jan;16(1):86-92. doi: 10.1200/JCO.1998.16.1.86. J Clin Oncol. 1998. PMID: 9440727 Clinical Trial.

2

Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity.

Maini CL, Sciuto R, Ferraironi A, Vici P, Tofani A, Festa A, Conti F, Lopez M. Maini CL, et al. Among authors: ferraironi a. J Nucl Cardiol. 1997 Nov-Dec;4(6):502-8. doi: 10.1016/s1071-3581(97)90008-8. J Nucl Cardiol. 1997. PMID: 9456190

3

Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment.

Vici P, Ferraironi A, Di Lauro L, Carpano S, Conti F, Belli F, Paoletti G, Maini CL, Lopez M. Vici P, et al. Among authors: ferraironi a. Clin Ter. 1998 Jan-Feb;149(921):15-20. Clin Ter. 1998. PMID: 9621483 Review.

4

Docetaxel in patients with anthracycline-resistant advanced breast cancer.

Vici P, Belli F, Di Lauro L, Amodio A, Conti F, Foggi P, Gionfra T, Morelli MF, Botti C, Ferraironi A, Lopez M. Vici P, et al. Among authors: ferraironi a. Oncology. 2001;60(1):60-5. doi: 10.1159/000055298. Oncology. 2001. PMID: 11150910 Clinical Trial.

5

111In-octreotide scintigraphy in small cell lung cancer.

Semprebene A, Ferraironi A, Franciotti G, Venturo I, Giunta S, Lopez M, Maini CL. Semprebene A, et al. Among authors: ferraironi a. Q J Nucl Med. 1995 Dec;39(4 Suppl 1):108-10. Q J Nucl Med. 1995. PMID: 9002764

6

Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy.

Sciuto R, Festa A, Tofani A, Pasqualoni R, Semprebene A, Cucchi R, Ferraironi A, Rea S, Maini CL. Sciuto R, et al. Among authors: ferraironi a. Clin Ter. 1998 Jan-Feb;149(921):43-7. Clin Ter. 1998. PMID: 9621488 Clinical Trial.

7

Myocardial 123I-MIBG kinetics in acutely hypothyroid patients with differentiated thyroid carcinoma.

Maini CL, Tofani A, Sciuto R, Ferraironi A, Festa A, Rea S. Maini CL, et al. Among authors: ferraironi a. Nucl Med Commun. 1999 Aug;20(8):719-26. doi: 10.1097/00006231-199908000-00006. Nucl Med Commun. 1999. PMID: 10451880

8

Somatostatin receptor imaging in CNS tumours using 111In-octreotide.

Maini CL, Sciuto R, Tofani A, Ferraironi A, Carapella CM, Occhipinti E, Mottolese M, Crecco M. Maini CL, et al. Among authors: ferraironi a. Nucl Med Commun. 1995 Sep;16(9):756-66. doi: 10.1097/00006231-199509000-00006. Nucl Med Commun. 1995. PMID: 7478408

9

[Immunoscintigraphy with 111-indium-labelled antimyosin antibodies in the assessment of muscle metastases. A case report].

Ferraironi A, Tofani A, Sciuto R, Cucchi R, Crecco M, Maini CL. Ferraironi A, et al. Radiol Med. 1994 Jan-Feb;87(1-2):165-8. Radiol Med. 1994. PMID: 8128026 Italian. No abstract available.

10

Clinical relevance of 111In-octreotide scans in CNS tumors.

Sciuto R, Ferraironi A, Semprebene A, Occhipinti E, Mastrostefano R, Crecco M, Mottolese M, Maini CL. Sciuto R, et al. Among authors: ferraironi a. Q J Nucl Med. 1995 Dec;39(4 Suppl 1):101-3. Q J Nucl Med. 1995. PMID: 9002762

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page